The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated with poor performance status and shortened survival in cancer patients. PATIENTS AND METHODS: The characteristics of Child Pugh A cirrhotic patients with HCC receiving sorafenib in our institution were retrospectively analyzed. Sorafenib plasma concentrations were determined at each visit. Toxicities were recorded during the first month of treatment, and sarcopenia was determined from baseline CT-scans. RESULTS: Forty patients (30 males) were included. Eleven (27.5%) were sarcopenic. Eighteen patients (45%) experienced a DLT during the first month of treatment. Sarcopenic patients experienced significantly more DLTs than non-sarcopenic patients did (82% versus 31%, p = 0.005). Grade 3 diarrhea was significantly more frequent in sarcopenic patients than in non-sarcopenic patients (45.5% versus 6.9%, p = 0.01), but not grade 3 hand foot syndrome reaction (9% versus 17.2%, p = 1). On day 28, median sorafenib AUC (n = 17) was significantly higher in sarcopenic patients (102.4 mg/l.h versus 53.7 mg/l.h, p = 0.013). CONCLUSIONS: Among cirrhotic Child Pugh A patients with advanced HCC, sarcopenia predicts sorafenib exposure and the occurrence of DLT within the first month of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Cited by
ESPEN expert group recommendations for action against cancer-related malnutrition
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P. C., Deutz, N. E. P., Erickson, N., Laviano, A., Lisanti, M. P., Lobo, D. N., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.017 · Cited by 1,305
Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review
Shachar, S. S., Williams, G. R., Muss, H. B., & Nishijima, T. F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.030 · Cited by 1,099
Understanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
Lean Tissue Imaging: A New Era for Nutritional Assessment and Intervention
Prado, C. M. M., & Heymsfield, S. B. (2014) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607114550189 · Cited by 550
Ryan, A. M., Power, D. G., Daly, L., Cushen, S. J., Ní Bhuachalla, Ē., & Prado, C. M. (2016) · Proceedings of the Nutrition Society · doi:10.1017/s002966511500419x · Cited by 542
Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma
Voron, T., Tselikas, L., Pietrasz, D., Pigneur, F., Laurent, A., Compagnon, P., Salloum, C., Luciani, A., & Azoulay, D. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000743 · Cited by 391
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes
Kazemi-Bajestani, S. M. R., Mazurak, V. C., & Baracos, V. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.09.001 · Cited by 313
Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact
Prado, C. M., Cushen, S. J., Orsso, C. E., & Ryan, A. M. (2016) · Proceedings of the Nutrition Society · doi:10.1017/s0029665115004279 · Cited by 300
Psutka, S. P., Carrasco, A., Schmit, G. D., Moynagh, M. R., Boorjian, S. A., Frank, I., Stewart, S. B., Thapa, P., Tarrell, R. F., Cheville, J. C., et al. (2014) · Cancer · doi:10.1002/cncr.28798 · Cited by 298
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
van Vugt, J. L. A., Levolger, S., Gharbharan, A., Koek, M., Niessen, W. J., Burger, J. W. A., Willemsen, S. P., de Bruin, R. W. F., & IJzermans, J. N. M. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12158 · Cited by 217
Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., Charnley, R. M., & Lyadov, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.11.006 · Cited by 174
Rier, H. N., Jager, A., Sleijfer, S., van Rosmalen, J., Kock, M. C. J. M., & Levin, M.-D. (2017) · The Breast · doi:10.1016/j.breast.2016.10.014 · Cited by 149
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
Fonseca, G. W. P. D., & von Haehling, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873954 · Cited by 25
Oncology-Led Early Identification of Nutritional Risk: A Pragmatic, Evidence-Based Protocol (PRONTO)
Muscaritoli, M., Bar-Sela, G., Battisti, N. M. L., Belev, B., Contreras-Martínez, J., Cortesi, E., de Brito-Ashurst, I., Prado, C. M., Ravasco, P., & Yalcin, S. (2023) · Cancers · doi:10.3390/cancers15020380 · Cited by 23
Metadata
- Authors
- Mir, O., Coriat, R., Blanchet, B., Durand, J.-P., Boudou-Rouquette, P., Michels, J., Ropert, S., Vidal, M., Pol, S., Chaussade, S., & Goldwasser, F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-30
- Volume
- 7
- Issue
- 5
- Pages
- e37563
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2006782694
- Cited by
- 304
- References
- 20
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.